Annual Scientific Meeting
Dr Cristiane Bergerot, Ph.D., is the head of Supportive Care at Oncoclinicas, Brazil. She completed a 3 year research fellowship in the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center in Duarte, California, USA. She has been working with cancer patients for almost 20 years as a clinician and as a researcher. She has received four merit awards from the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation and was selected for the prestigious SWOG Young Investigator Course. She is past recipient of the Barry Hoeven Memorial Kidney Cancer Research Grant from Kure It in 2020, the Global Oncology Young Investigator Award (GOYIA) from the Conquer Cancer Foundation in 2021, and the Psychosocial Focus Award from the Kidney Cancer Association in 2021. Currently, she is serving as the quality-of-life Chair of two ongoing clinical trial in the US and France. She is committed to bettering the lives of patients with cancer through (1) obtaining a detailed understanding of their quality of life and (2) addressing their quality of life through novel, targeted interventions.
Dr Elena Castro is a Consultant Medical Oncologist in prostate cancer at Hospital 12 de Octubre in Madrid. Dr Castro studied Medicine and obtained a PhD from the University of Salamanca. After training in Medical Oncology, she completed a fellowship in Cancer Genetics at the Institute of Cancer Research and The Royal Marsden Hospital. In 2013, she moved back to Spain and joined the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Center. Dr Castro is a translational clinician-scientist whose research interest span preclinical research to clinical trials. Her work has addressed the clinical implications of genetic and genomic variants in prostate cancer and has been involved in several clinical trials investigating new treatment strategies for patients with advanced prostate cancer. Dr Castro serves on the European Society of Medical Oncology faculty panel for prostate cancer and is an elected member of the translational medicine and precision medicine working group.
Dr. Paul Nguyen is an internationally-recognized expert in prostate cancer clinical care and research. He has published over 350 original research articles and has national leadership as Co-Chair of the National Cancer Institute's GU Steering Committee, Chair of the ARS/ACR Appropriateness Criteria Committee for Prostate Cancer, and Chair of the ASTRO Annual Refresher Course. He is the Principal Investigator of the multi-center randomized FORMULA-509 trial and the national NRG Oncology GU-009/PREDICT-RT trial, and Co-Chair of the international randomized ENZARAD trial. His research is supported by an NIH R-01 grant. He serves as the DF/BWCC Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the Department of Radiation Oncology, Professor at Harvard Medical School, and Baldwin-Politi Distinguished Chair in Oncology at Brigham and Women's Hospital where he is also associate director of the Harvard Radiation Oncology Program residency. He received his AB from Harvard College, MD from Harvard Medical School, MBA from the MIT Sloan School of Management, and completed his residency at the Harvard Radiation Oncology Program where he served as chief resident.
Prof Ravindran Kanesvaran is a Senior Consultant and Chairman of the Division of Medical Oncology of the National Cancer Centre Singapore. He is also an Associate Professor and the SingHealth- Duke NUS Distinguished Professor in Geriatric Oncology at Duke-NUS Medical School. He is actively involved in graduate medical education and is the Past Programme Director of the Medical Oncology Senior Residency Programme. His research interests include genitourinary (GU) oncology and geriatric oncology. He is currently the past President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is the Past President of the International Society of Geriatric Oncology (SIOG) and past council member of ESMO. He has published over 220 peer reviewed manuscripts. He is vice-chairman of the Singapore Cancer Society (SCS). He was recently awarded the Fellow in ESMO award ( FESMO).
Dr. Hamilton is a urologic oncologist at Princess Margaret Cancer Centre and Associate Professor in the Department of Surgery (Urology) at the University of Toronto, Canada. His clinical and research interests are in prostate cancer and testicular cancer. In prostate cancer, he is exploring the role of pharmacogenomics to personalize chemoprevention, with a particular interest in statin medications. He has interest in oligometastatic disease and molecular imaging modalities. In testicular cancer his interests include novel biomarkers and studying means to minimize treatment morbidity. Dr. Hamilton trained at the University of Toronto; completed a Masters of Public Health at The University of North Carolina at Chapel Hill and a research fellowship at Duke University. He completed fellowship at Memorial Sloan-Kettering Cancer Centre.
Professor Bertrand Tombal is Chairman of the Department of Surgery and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. Professor Tombal is a member of the Royal Academy of Medicine of Belgium. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer.